Tango Therapeutics, Inc. 8-K

What Happened Tango Therapeutics (TNGX) increased its board size to seven directors and on June 19, 2026 appointed Robert Azelby as a Class II director. Mr. Azelby will serve until the 2029 annual meeting, when he will stand for election by stockholders. The Board determined he is independent and, effective June 23, 2026, added him to the Compensation Committee and the Nominating and Corporate Governance (NCG) Committee. The company issued a press release on June 22, 2026 announcing the appointment.

Key Details

• Board change: size increased to seven directors; Azelby appointed June 19, 2026 as Class II director (term through 2029 annual meeting).
• Equity compensation: stock option to purchase 35,910 shares at $27.97 per share and RSUs for 5,740 shares.
  • Option vests in 36 substantially equal monthly installments over 3 years; RSUs vest in three equal annual installments over 3 years.
  • Vesting ceases if Mr. Azelby leaves the Board before vesting.
• Cash compensation: annual retainers of $45,000 (board), $7,500 (Compensation Committee), $5,000 (NCG Committee), paid quarterly and prorated.
• Governance/legal: entered into the company’s standard director indemnification agreement; Board found him independent; no related-party transactions reported.

Why It Matters This filing informs investors about a governance change—adding an independent director and expanding committee membership—which can affect oversight of executive pay and board nominations. The equity awards and retainers are standard for non-employee directors but will result in potential future share issuance as awards vest and options are exercised. There are no reported related-party concerns; the appointment is positioned as a routine governance update rather than a management change.